You are on page 1of 8

Academy of Pharmaceutical

Sciences
John Wahlich, Jayne Lawrence, Eddie French
1
APS Mission and Aims

• Mission:
– Championing innovation and opportunity in
Pharmaceutical Sciences for the delivery of medicines
• Aims
– Promote the Pharmaceutical Sciences to stakeholders
to facilitate understanding and achieve engagement
– Share learning, drive collaboration, partnership and
innovation
– Deliver insights into industry and academic roles for
emerging scientists
2
APS Strategic Themes
The mission of the Academy of Pharmaceutical Sciences is to champion innovation
and opportunity in Pharmaceutical Sciences for the delivery of medicines.
Influence
Policy
•More investment in Pharm Sciences in UK
•APS view sought by policy makers and TSB
•APS recognised as only professional group representing Pharm Sciences
•Senior Executives recognise the influence from and return on investment in APS
Promote
Careers
•Strengthen training and development of young scientists by supporting early career development
•Build APS membership amongst students
•Mentor post-grads and PhDs in academia
•Establish connection with TSB for research projects
Further
Scientific
knowledge
•Support Focus Groups to further scientific knowledge
•Increase quantity of hard outputs/papers
•Influence direction of research funding
Represent
Pharma
Sciences
•Establish APS reputation for balanced independent view of Pharm Sciences in UK
•Extend representation through engagement with pharma ‘mid tier’, CROs, CMOs and SMEs
•Increase membership amongst pharma scientist population
APS Enablers
 Increase
organisational
membership
 Robust
sponsorship
income streams
 Clear APS brand
definition


3
Focus Group Current Chairperson(s)
Emerging Scientists and
Development
Helen Barker / Claire
Thompson / Geoff Davison
Biomolecules and Vaccines Kevin King
Biopharmaceutics and oral drug
delivery
Mark McAllister
Inhalation Eddie French
Material Sciences Michael Leane
Pharmacognosy Michael Heinrich
Process Engineering, Product
Formulation and Manufacturing
Kendal Pitt
Anti-infectives (Microbiology) Brendan Gilmore
Skin Forum Majella Lane
APS Focus Groups
4
APS
• The APS is a not-for-profit organisation funded
through membership and sponsorship
• Of attendees today less than 25% are
members of APS
• If you like what we’re doing and want to
support the Pharmaceutical Sciences in the UK
join the APS!
– £60 / year or £15 for students
http://www.apsgb.co.uk/default.asp
5
Medicines for Older Adults
• Meeting Stevenage 13 March 2013
Medicines for older adults: Learning from practice to
develop patient centric drug products
• Jointly organised by the Academy of Pharmaceutical
Sciences (APS), the Geriatric Medicine Society and UCL
School of Pharmacy
• The event created the platform to discuss the provision
of medicines for older adults from a pharmaceutical
sciences perspective
• Meeting commentary Int J Pharm. 2013 Nov
1;456(1):251-7. doi: 10.1016/j.ijpharm.2013.07.038.
Epub 2013 Aug 3. (35 references)

6
Medicines for Older Adults
• Meeting discussed
– Demographics of older adults
– Physiological aspects of ageing
– Medicines and ageing from a clinical, pharmacy and regulatory
perspective
– ADRs, polypharmacy, adherence, formulation and delivery aspects
• Conclusion
– Parallels with paediatric medicines
– More could be done to improve the delivery of medicines to older
adults
– Opportunity for collaboration to achieve this

‘The use of medications in older patients is arguably the single
most important health care intervention in the industrialized
world’. (Avorn 2010)
Avorn, J., 2010. Medication Use in Older Patients: Better Policy Could Encourage Better Practice. JAMA 304,
1606-1607.
7
Age Related Medicines Focus Group
APS can provide the framework for collaboration
• Web site
• Access to membership and Linked-in contact networks
• Links with other Focus Groups
• Support (financial and organisational) for workshops / conferences /
symposia
• APS Pharm Sci 2014 Conference September
• Potential for session at FIP Conference Bangkok (August 2014)
Outcome from meeting
• Ownership going forward
– Committee identified
• Next steps agreed
It’s your meeting we’re here to facilitate!
8